Traws Pharma, Inc. ((TRAW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Traws Pharma, Inc. is conducting a Phase 1 clinical study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Dose Escalation (With Optional Food Effect) Study of Orally Administered TRX-100 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of TRX-100 in Healthy Volunteers. The study aims to assess the pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRX-100 and its major active metabolite TRX-101 in healthy volunteers, marking a significant step in understanding the drug’s potential.
Intervention/Treatment: The study tests TRX-100, a CEN inhibitor administered in capsule form, against a placebo. The drug is designed to be taken once daily, with the goal of evaluating its safety and effectiveness in healthy individuals.
Study Design: This interventional study is randomized and double-blind, involving four cohorts of participants who receive either TRX-100 or a placebo. The primary purpose is treatment, and the sequential intervention model ensures a structured approach to dose escalation.
Study Timeline: The study began on December 16, 2024, with the last update submitted on December 25, 2024. These dates are crucial as they indicate the study’s current recruiting status and the timeliness of the information provided.
Market Implications: The progress of this study could influence Traws Pharma’s stock performance, as positive results may boost investor confidence and interest. In the competitive pharmaceutical industry, advancements in clinical trials like this one are closely watched by investors and competitors alike, potentially impacting market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.